OMCL — Omnicell, Inc.

Is OMCL overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Health Information Services

Neutral As of November 17, 2026

Omnicell, Inc. (OMCL) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Health Information Services) last closed at $35.44. The rating moved from Oversold to Neutral on November 17, 2026.

AI analysis

Omnicell, Inc. (OMCL) is positioned as a leading provider of medication management and pharmacy automation with a meaningful installed base and recurring service revenue that supports revenue visibility. Growth catalysts include rising specialty pharmacy and infusion volumes, continued hospital demand for automation to control costs and improve safety, and potential software/analytics monetization from installed systems. Financial health appears supported by recurring contracts and replacement cycles, though outcomes depend on execution of higher-margin service expansions and disciplined cost management. Overall, upside is tied to successful conversion of installed base to software/services and steady hospital spending; downside stems from regulatory shocks, weaker capital spending, and competitive displacement.

Key factors

  • Market-leading position in medication dispensing, pharmacy automation and clinical workflow solutions with a wide installed base and recurring service revenue.
  • Exposure to specialty pharmacy, infusion and biopharma services benefits from secular growth in injectable and specialty therapies and distributor channel shift.
  • Secular hospital and health-system demand for automation to reduce labor/cost pressures and improve medication safety supports ongoing replacement and software/service upsell.
  • Defensive healthcare flows into large pharma and medtech amid macro uncertainty can support relative valuation stability for established healthcare equipment providers.
  • Installed-base economics and recurring maintenance/contracts provide revenue visibility and potential margin leverage through software and analytics monetization.

Risks

  • Regulatory headwinds tied to Medicare Advantage anti-fraud and program-integrity measures that could change payer economics and hospital/pharmacy reimbursement dynamics.
  • Hospital and health-system capital spending is cyclical and sensitive to interest rates and budget pressures, which can delay automation/upgrade cycles.
  • Competition from other medtech vendors, specialty pharmacy/fulfillment players, and potential insourcing by large health systems could pressure share and pricing.
  • Execution risk on product development, software monetization, and any M&A integration; failure to convert installed base to higher-margin services would limit upside.
  • Macro and market sentiment risk: cautious risk-on tone and rate-path uncertainty can compress multiples and restrain near-term upside.
  • Supply-chain or component constraints that could delay deployments or increase costs.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for OMCL — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.